120 results about "Cord blood" patented technology

The invention discloses a method for culturing CIK (Cytokine-Induced Killer) cells and application thereof. The method comprises the following steps: recovering cord blood, mixing and centrifuging the recovered cord blood and a buffer solution, re-suspending and precipitating, centrifuging again to obtain cord blood mononuclear cells, inoculating the cord blood mononuclear cells into an activation culture medium, and culturing to obtain the CIK cells, the buffer solution contains L-proline, human recombinant DNA enzyme and angelica polysaccharide. According to the method, the mononuclear cells can be separated from the umbilical cord blood preserved by liquid nitrogen, the utilization rate of the umbilical cord blood which can only be discarded due to insufficient cells is increased, the traditional lymphocyte separation process is optimized, the recovery rate of the mononuclear cells is increased, and the cost is reduced. The method provided by the invention can be used for culturing dozens to ten billions of CIK cells from a small amount of cryopreserved cord blood, and has huge advantages in the field of CIK cell culture and application.

The invention relates to a composition containing a leukocyte extract and a white tomato extract and application of the composition in cosmetics, and belongs to the technical field of cosmetics and biology. Specifically, animal umbilical cord blood is selected as a raw material, and the leukocyte extract is obtained through the steps of extraction and purification; meanwhile, white tomato polypeptide is extracted, and further separation is performed to obtain the polypeptide as shown in SEQ ID NO.1-2; the leukocyte extract and the white tomato polypeptide have good safety, have remarkable antioxidant and whitening effects through synergism, can be safely used in the field of cosmetics, and expand the application prospects of the leukocyte extract and the white tomato polypeptide.

The utility model provides dialysis and separation equipment for umbilical cord blood. The dialysis and separation equipment comprises a first separation plate, a second separation plate, a bag and dredging units, wherein the first separation plate and the second separation plate are composed of filter membranes and impermeable membranes, the bag is made of flexible materials, and the dredging units are arranged on the two sides of the bag and used for squeezing. The filter membrane and the impermeable membrane are tightly combined to form an outlet, and the bag is divided into three cavities which are respectively used for treating umbilical cord blood and controlling liquid flow through a catheter and a valve. The dredging unit periodically extrudes the bag through the extrusion part and the control part, so that the filter membrane is prevented from being blocked. The equipment can effectively separate blood components through the matching of the filter membranes with different pore diameters and functions, and realizes a reliable, effective, simple and economical umbilical cord blood dialysis and separation mode.

The invention provides a preparation method and application of super memory NK cells. The method comprises the following steps: S1, separating from peripheral blood or umbilical cord blood to obtain mononuclear cells; s2, culturing the mononuclear cells by using an NK activation culture medium; s3, separating CD3-CD56 + cells from the cultured mononuclear cells, so as to obtain purified NK (Natural Killer) cells; and S4, stimulating the NK cells by using a memory factor to induce the NK cells into memory-like NK cells, and culturing the memory-like NK cells by using an amplification culture medium to prepare the super-memory NK cells. Before the NK sorting kit is used for sorting and purifying the cells, the NK activation culture medium containing IL-2, IL-15 and IL-18 is used for conducting induction culture on the mononuclear cells, the NK cells can be activated, the total cell amount is greatly increased, the number of the NK cells obtained through follow-up sorting is increased, the problems that the number of the NK cells purified through PBMC in the early stage is small, and the culture difficulty is large are solved, and the cell quality is improved. The total cell quantity of the finally cultured super memory NK cells is increased.

The invention provides an immortalized NK cell line SZ093 derived from healthy human umbilical cord blood as well as a preparation method and application of the immortalized NK cell line SZ093. The immortalized NK cell line SZ093 derived from the healthy human umbilical cord blood is preserved in Guangdong Microbial Culture Collection Center on September 26, 2025, and the preservation number is GDMCC No: 67036. The immortalized NK cell line SZ093 derived from the healthy human umbilical cord blood, provided by the invention, can still keep good multiplication capacity and high survival rate in a long-time (more than one year) culture process, and has high killing capacity on tumor cells.

The invention relates to the technical field of cosmetics, and discloses an umbilical cord blood moisturizing essence composition, an umbilical cord blood moisturizing essence as well as a preparation method and application of the umbilical cord blood moisturizing essence. The composition contains a hydrolyzed placenta extract, placenta protein, an umbilical cord extract, a guava fruit extract, a radix gentianae extract, decapeptide-4, nonapeptide-1, a lactobacillus fermentation product and a yeast fermentation product filtrate. The umbilical cord blood moisturizing essence prepared from the composition has multiple effects of moisturizing, repairing and resisting aging, and is mild, safe, excellent in stability and high in active ingredient retention rate.

The invention relates to the technical field of medicines, in particular to application of combined use of NK cells and a GD2 antibody in preparation of a medicine for treating neuroblastoma. The NK cell and the GD2 antibody are jointly used to prepare a medicine for treating neuroblastoma. In-vivo and in-vitro experiments find that the umbilical cord blood NK cell combined with the GD2 antibody can significantly enhance the tumor killing ability and inhibit the growth of neuroblastoma cells, provides a new therapeutic medication scheme for the treatment of neuroblastoma, and has a good application prospect in the prevention and treatment of neuroblastoma.

The application belongs to the technical field of cell culture, and particularly relates to umbilical cord blood-derived endothelial cell culture additives, an endothelial cell culture method and application. The umbilical cord blood-derived endothelial cell culture additives comprise activated platelet-rich plasma and at least one of miR-132 and miR-193b-3p high expression and miR-155 low expression exosomes. The application further provides an endothelial cell culture medium comprising the umbilical cord blood-derived endothelial cell culture additives, and the culture medium can significantly improve the growth state of HUVEC cells and effectively reduce or even avoid the vacuolization phenomenon in the culture process.

The invention discloses application of an umbilical cord blood exosome in preparation of a medicine for treating ophthalmic diseases caused by aging. It is found that the umbilical cord blood exosome can improve the biological characteristics of senescent trabecular meshwork cells, relieve the senescence characteristics of the trabecular meshwork cells, improve the DNA damage repair capacity of the cells, promote proliferation of the trabecular meshwork cells and effectively maintain the stability of cell nucleuses, and then growth and division of the cells are supported. The umbilical cord blood exosome shows a remarkable anti-aging effect in treatment of ophthalmic diseases caused by aging, can effectively improve the biological function of trabecular meshwork cells, slow down the aging process and promote cell proliferation and repair, and has wide application potential.

The present invention provides a cell population and a method for obtaining the same. The cell population of the present invention is obtained by culturing mononuclear cells derived from bone marrow, umbilical cord blood or peripheral blood in a culture medium containing four or less factors selected from stem cell factor, interleukin 6, FMS-like tyrosine kinase 3 ligand, thrombopoietin and vascular endothelial cell growth factor, and serum.

The invention belongs to the field of biomedicine, and particularly relates to a detection method, an evaluation method and application of umbilical cord blood-derived natural killer cells. The detection method disclosed by the invention is used for carrying out related detection and data analysis on the natural killer cells from umbilical cord blood, is high in pertinence and can be used as a detection method for delivering the NK cells from a warehouse. According to the evaluation method, the relationship between the NK function related protein and the cell killing ability is determined, the killing ability of the NK cells is judged by detecting functional protein indexes CD3, NKG2A, CD56, CD16, NKP46 and CD107A of the natural killer cells and calculating NK scores of samples based on detection results, the sensitivity and specificity are high, and the method can be used for evaluating the killing ability of the NK cells.

The invention belongs to the technical field of biological medicine, and particularly relates to a frozen umbilical cord blood NK cell amplification method which comprises the following steps: S1, umbilical cord blood NK cell separation; s2, performing serum-free culture; s3, performing dynamic amplification; and S4, performing cryopreservation and resuscitation verification. According to the invention, after unfreezing, a culture medium containing a TGF-beta inhibitor (Galunissertib) is firstly used for pretreatment for 24 hours, so that an inhibitory signal is blocked, and the survival rate is increased. The dynamic amplification adopts three-stage metabolism regulation: stage 1: in a low-oxygen environment, using a culture medium containing SCF + FLT3L + IL-7 to promote activation of NK cells in a stationary period; stage 2: under a normal oxygen condition, switching to IL-12 + IL-18 + IL-21, and adding an antioxidant NAC to reduce ROS accumulation; and stage 3: pulse-type stimulation: adding CD16 cross-linked magnetic beads every 48 hours to enhance cytotoxicity.

The utility model relates to the technical field of biological experiment instruments, in particular to a hanging accessory used in the separation process of umbilical cord blood hematopoietic stem cells, which is mainly used for being connected with a grid at the top of a biological safety cabinet and comprises a fixed end connected with the grid at the top of the biological safety cabinet, and a hook used for being connected with a blood bag is arranged below the fixed end. The fixing end comprises a clamping ring, a torsional spring clamping opening capable of being clamped into a grid is formed in the clamping ring, a limiting sliding groove is formed in the inner side of the clamping ring, and a limiting rod capable of moving up and down along the inner wall of the clamping ring is slidably connected into the limiting sliding groove. A reset spring capable of resetting the limiting rod upwards is arranged between the bottom of the limiting sliding groove and the limiting rod. The technical problems that in the prior art, a blood bag is connected with a grid in a biological safety cabinet through a paper clip, then the blood bag is hung, shaking is large, the blood bag is prone to falling off, a sample possibly needs to be centrifuged many times, and the motility rate of the sample is affected are solved.

The present disclosure discloses a method for isolating osteoprogenitors like mesenchymal stem cells (MSCs) from clotted bone marrow and culturing with a platelet lysate obtained from a combination of discarded umbilical cord blood and maternal blood platelet-rich plasma (instead of non-human animal origin serum) and differentiating those MSCs into osteoblasts under sterile conditions for further therapeutic applications. Particularly, the present disclosure relates to a method for expansion of osteoblasts to make cell therapy products with a fixed cell dose, which are characterized and later cryopreserved for future use through its cell culture process. Further, the present disclosure relates to identifying specific gene expression from MSCs to osteoblast formation, an in-vitro differentiation process that replicates the in-vivo bone remodelling system.

The invention relates to the field of biomedicine, and discloses application of EPTMPA in hematopoietic stem cell in-vitro amplification culture. The invention identifies a brand-new novel small molecule compound EPTMPA capable of remarkably promoting in-vitro expansion and in-vivo transplantation of hematopoietic stem cells and hematopoietic progenitor cells of umbilical cord blood, and the novel small molecule compound EPTMPA can remarkably promote in-vitro expansion of CD34 + hematopoietic stem cells and hematopoietic progenitor cells and maintain the stem property and differentiation potential. EPTMPA is a new discovery and new way for in-vitro amplification of hematopoietic stem cells, but needs more studies to understand the action mechanism, targeting genes and proteins of the hematopoietic stem cells and the regulation effect on self-renewal and differentiation balance of the stem cells. The researches are of great significance to clinical application and product development in the future.

The application belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of umbilical cord blood plasma-derived extracellular vesicles and related bioactive molecules thereof in treatment of Alzheimer's disease. Specifically, the application isolates extracellular vesicles (UCBP-sEVs) from umbilical cord blood plasma, which has the effect of improving Alzheimer's disease. Further research finds that high enrichment of miR-16-2-3p therein is a key molecule for mediating treatment of Alzheimer's disease. miR-16-2-3p targets and inhibits expression of ROCK2, reduces phosphorylation level of TFEB and promotes nuclear translocation of the same, activates microglial autophagy-lysosome pathway, and thus promotes phagocytosis and degradation of intracerebral beta amyloid, and therefore has good practical application value.

Provided herein are populations of ex vivo expanded umbilical cord blood-derived regulatory T cells. Also provided are methods of making and using the same.

Described herein are novel methods for fractionating and isolating platelets, platelet- and extracellular vesicle-derived growth factors, exosomes, globulins, fibrinogen and albumin, and methods of using the isolated platelets, platelet and extracellular vesicle-derived growth factors, exosomes, globulins, fibrinogen and albumin for regenerating tissue in a subject, treating fibrinogenemia or a clotting deficiency in a subject, treating ischemia and hypoxia, treating dry-eye syndrome, an orthopedic disorder, or a dental disorder in a subject. Also described herein are growth media for culturing mammalian (e.g., human) cells.

The invention provides a preparation method and application of an anti-IL-11 antibody modified Treg cell, and belongs to the technical field of genetic engineering.The preparation method of the anti-IL-11 antibody modified Treg cell comprises the steps that after the Treg cell and umbilical cord blood pluripotent stem cells are co-cultured, the Treg cell is separated and recycled, an anti-IL-11 antibody is adopted for modification, and the anti-IL-11 antibody modified Treg cell is obtained; the nucleotide sequence of the anti-IL-11 antibody is as shown in SEQ ID NO. 2 in the sequence table. In the co-culture process, stem cells are used for providing an immune microenvironment, promoting Treg cell amplification and enhancing the inhibition ability of Treg cells, and obtaining the specific recognition ability of pancreas islet beta cell antigens, so that autoimmune attacks are inhibited more accurately; the nucleotide sequences of the heavy chain and the light chain of the anti-IL-11 antibody are optimized, and the anti-IL-11 antibody has higher efficacy in treatment of diabetic mice.

The invention belongs to the technical field of medicines, and particularly relates to preparation of CD73 positive NK cells of umbilical cord blood from different starting sources and application of the CD73 positive NK cells to treatment of Alzheimer's disease. The CD73 + NK cells differentiated from different initial cell types (CD34 positive cells, CD3 negative / CD56 positive cells and CD56 negative cells) of umbilical cord blood are studied, it is found that all the initial cell types of umbilical cord blood sources can be differentiated into the CD73 + NK cells, 34 +-73-NK cells show a higher growth rate, 56-73-NK cells show higher cytotoxicity, and the CD73 + NK cells can be differentiated into the CD73 + NK cells. And the overall effect of the 56-73-NK cell is superior to that of the 34 < + >-73-NK cell. Further research shows that the CD73 + NK can inhibit activation of STZ injection mouse hippocampal microglia and astroglia, so that the neuroinflammation of the hippocampal is reduced, and a new solution is expected to be provided for treatment of AD.

Provided are methods and compositions conditioning a patient for an allogeneic transplantation, wherein the patient's hematopoietic stem cells (HSCs) are depleted with an HSC-depleting composition and the patient is then administered allogeneic cells selected from bone marrow cells, umbilical cord blood cells, hematopoietic stem and progenitor cells (HSPCs), peripheral blood CD34+ cells, and peripheral blood CD34+ and CD90+ cells; optionally the patient is also administered a medicament selected from the group consisting of a T-cell depleting or inhibiting antibody or antibody fragment, NK-cell depleting or inhibiting antibody or antibody fragment, immunosuppressive drug, and any combination thereof. The HSC-depleting composition comprises a compound selected from the group consisting of: an antibody or antibody fragment with specific binding affinity to a protein displayed at the HSC surface, a conjugate comprising an HSC-recognition molecule and a toxin, and any combination thereof.

A method for alleviating fatigue, comprising administering to a patient in need thereof an effective amount of a human umbilical cord blood composition, which comprises hematopoietic progenitor cells, monocytes, lymphocytes, granulocytes, or a combination thereof.

To provide a population of cord blood-derived regulatory T cells expanded ex vivo. To provide a method for producing a population of cord blood-derived regulatory T cells expanded ex vivo, and a method for using the same.SOLUTION: Provided is a population of human Treg cells comprising at least about 1 * 10 8 human Treg cells, wherein (i) ≥ 60% are CD4 + CD25 + and (ii) ≤ 10% are CD4 - CD8 +, wherein said human Treg cells are immunosuppressive.SELECTED DRAWING: Figure 1

The present application relates to a kind of compositions containing leukocyte extract and white tomato extract and its application in cosmetics, belong to the field of cosmetics and biotechnology. Specifically, the present application selects animal umbilical cord blood as raw material, obtains leukocyte extract by extraction, purification step;At the same time, white tomato polypeptide is extracted, and further separation obtains the polypeptide described in SEQ ID NO.1-2;The leukocyte extract and white tomato polypeptide have good safety, and the both synergies have significant antioxidant and whitening effect, can be safely used in the field of cosmetics, expands the application prospect of leukocyte extract and white tomato polypeptide.

The present invention relates to a process for isolating Small Extracellular Vesicles secreted by umbilical cord blood mononuclear cells (UCBMNCs) and compositions comprising said Small Extracellular Vesicles, which are useful to be applied to autoimmune diseases therapeutics or prophylactics and / or cosmetic purposes.The proposed process for isolating UCBMNCs Small Extracellular Vesicles comprises three main steps: i) a first step of sequential centrifugation, ii) a second step of microfiltration combined with ultrafiltration (UF), and iii) a third step of size exclusion chromatography (SEC) and aims to achieve highly pure Small Extracellular Vesicles and in a higher yield.The SEVs compositions comprise specific type of proteins, RNA and lipids, that enables them to be very effective when applied to inflammatory and autoimmune diseases therapeutics, such as psoriasis, lupus, atopic dermatitis, eczema, etc. and also to cosmetic or prophylactic compositions.Therefore, the present invention lays in the technical domain of pharmaceuticals, medicine, cosmetics, research and development in cellular biology and appliances thereof.

The invention belongs to the technical field of biology, and particularly relates to an embryo in-vitro rotating culture method. The method comprises the following steps: culturing an embryo in an embryo culture solution, wherein the embryo culture solution contains fresh rat serum, antibiotics, ascorbic acid or a derivative thereof, pyruvic acid or a salt thereof, glutamine, a buffer salt and optional glucose; the embryo culture solution does not contain human umbilical cord blood serum; the use of human umbilical cord blood serum is avoided, so that the embryo rotating culture system can be quickly popularized; the method has the advantages that the method is simple and easy to operate, and further limits and adopts fresh rat serum and adjusts the oxygen concentration in different periods, so that the embryo proportion of blood continuously flowing in the egg sac blood vessel in the E7.5 + 3day period can be increased, the rapid flowing of the blood in the egg sac blood vessel in the E7.5 + 5day period of the mouse embryo is realized, and the in-vitro culture process of the mouse embryo E7.5-E7.5 + 6day is completed.

The application belongs to the technical field of biomedical materials and regenerative medicine, and provides a composite nano hydrogel and application thereof in repair of diabetic wound surface. The three-dimensional porous nano hydrogel framework formed by composite crosslinking of HA-3APBA, PVA and lithium clay nanosheet is used as a carrier, antioxidant small molecules NAC and VC are double-loaded, and inactivated umbilical cord serum is dispersed and compounded. In view of the pathological characteristics of high oxidative stress and sustained inflammation of the diabetic wound surface, the application removes active oxygen through the antioxidant small molecules, remodels the wound microenvironment, protects and cooperates with the umbilical cord serum to play the roles of promoting angiogenesis, collagen deposition and re-epithelialization, and solves the problems of easy inactivation of growth factors, prolonged inflammation and healing stagnation of the diabetic wound surface. Animal experiments show that the composite nano hydrogel significantly improves the healing speed and quality of the diabetic wound surface, and can be used for preparing drugs for treating diabetic foot ulcers, diabetic chronic ulcers and high oxidative stress difficult-to-heal wound surfaces.

Provided are methods and compositions conditioning a patient for an allogeneic transplantation, wherein the patient's hematopoietic stem cells (HSCs) are depleted with an HSC-depleting composition and the patient is then administered allogeneic cells selected from bone marrow cells, umbilical cord blood cells, hematopoietic stem and progenitor cells (HSPCs), peripheral blood CD34+cells, and peripheral blood CD34+ and CD90+ cells; optionally the patient is also administered a medicament selected from the group consisting of a T-cell depleting or inhibiting antibody or antibody fragment, NK-cell depleting or inhibiting antibody or antibody fragment, immunosuppressive drug, and any combination thereof. The HSC-depleting composition comprises a compound selected from the group consisting of: an antibody or antibody fragment with specific binding affinity to a protein displayed at the HSC surface, a conjugate comprising an HSC-recognition molecule and a toxin, and any combination thereof.

The utility model relates to the technical field of umbilical cord blood separation, and particularly discloses an umbilical cord blood separation preparation bag which comprises a plurality of blood bags, a main pipeline, a three-way valve, a needle head and a Luer taper. Wherein each blood bag is used for storing umbilical cord blood in the blood collection bag; one end of the main pipeline is communicated with the plurality of blood bags; an outlet of the three-way valve communicates with the main pipeline; the needle is communicated with one inlet of the three-way valve; the Luer taper is communicated with the other inlet of the three-way valve; the Luer taper is used for being connected with an injector so that the injector can be communicated with the blood bag. By means of the arrangement, when the needle head is communicated with the blood collection bag, transfer of umbilical cord blood from the blood collection bag to the blood bag can be completed; when the Luer taper is communicated with the injector, the reagent in the injector can be smoothly injected into the blood bag, leakage is avoided, and the safety of reagent adding is improved. Wherein the reagent is a hematopoietic stem cell separating medium.

The invention discloses an in-vitro amplification method for improving the purity of natural killer cells. The use combination of the cell factors is IL-2, IL-15, IL-18 and IL-21, the culture of the umbilical cord blood NK cells is optimized mainly from the aspects of the factor combination used for culturing the NK cells, the use concentration and the like, CD3-CD56 + positive indexes all reach 80% or above, and the amplification rate reaches 100 times or above. The method is also suitable for large-scale culture of peripheral blood NK cells, the CD3-CD56 < + > positive rate reaches 99.0% or above, the amplification rate reaches 1000 times or above, and the killing rate of K562 cells is 30% or above when the effect-target ratio is 1: 1.